 Canadian Atrial Fibrillation Anticoagulation CAFA Study Canadian Atrial Fibrillation Anticoagulation Study randomized double-blind placebo-controlled trial potential warfarin systemic thromboembolism inherent risk hemorrhage result publication positive studies similar design objective study completion planned recruitment patients patients Permanent discontinuation study medication warfarin-treated placebo-treated patients target range international normalized ratio warfarin-treated patients international normalized ratio target study days study days study days Fatal major bleeding annual rates warfarin-treated placebo-treated patients Minor bleeding patients warfarin placebo primary outcome event cluster nonlacunar stroke noncentral nervous systemic embolism fatal intracranial hemorrhage Events primary analysis efficacy days permanent discontinuation study medication annual rates primary outcome event cluster warfarin-treated placebo-treated patients relative risk reduction confidence limits